- Conditions
- Parkinson's Disease, Dyskinesia
- Interventions
- Sarizotan, Placebo
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1801–1824
of 5,351
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Allogeneic HSCT, Fludarabine, Melphalan, Bortezomib, Ixazomib, Placebo
- Procedure · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Duarte, California • Tampa, Florida + 11 more
- Conditions
- Asthma
- Interventions
- BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF pMDI 320/9 μg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 2,187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 88
- States / cities
- Chandler, Arizona • Tempe, Arizona • Tucson, Arizona + 78 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Pracinostat, Azacitidine
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 25
- States / cities
- Duarte, California • San Diego, California • Augusta, Georgia + 21 more
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Interventions
- Symplicity Spyral™ multi-electrode renal denervation system, Sham Procedure
- Device · Procedure
- Lead sponsor
- Medtronic Vascular
- Industry
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 30
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more
- Conditions
- HIV Infections
- Interventions
- Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 825 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 97
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
- Conditions
- Coronary Artery Disease
- Interventions
- Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation, Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Bakersfield, California • La Jolla, California + 67 more
- Conditions
- Fabry Disease
- Interventions
- PRX-102 (pegunigalsidase alfa), agalsidase beta
- Biological
- Lead sponsor
- Protalix
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Orange, California + 11 more
- Conditions
- Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Pazopanib, Temozolomide, Trabectedin, Transthoracic Echocardiography Test
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 120 more
- Conditions
- Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET), Unspecified Childhood Solid Tumor, Protocol Specific, Wilms Tumor and Other Childhood Kidney Tumors
- Interventions
- pharmacological study, laboratory biomarker analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 16 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Long Beach, California • Los Angeles, California + 31 more
- Conditions
- Kidney Cancer, Metastatic Cancer
- Interventions
- sorafenib tosylate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 12
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 9 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- Fecal microbiota
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Months and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Coagulopathy, Hemorrhage
- Interventions
- Autologous Spray Dried Plasma
- Combination Product
- Lead sponsor
- Velico Medical
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Milwaukee, Wisconsin • West Bend, Wisconsin
- Conditions
- Immune Thrombocytopenic Purpura (ITP)
- Interventions
- Mezagitamab, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 25
- States / cities
- Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more
- Conditions
- Chronic Myelogenous Leukemia - Chronic Phase
- Interventions
- Nilotinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Augusta, Georgia • Beech Grove, Indiana + 8 more
- Conditions
- Aging
- Interventions
- Memory decision type
- Behavioral
- Lead sponsor
- Caitlin Bowman
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Tucson, Arizona + 61 more
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- IOV-4001
- Biological
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more
- Conditions
- Gerd, Eosinophilic Esophagitis
- Interventions
- MuVI Esophageal mucosal impedance testing
- Device
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Lymphoma
- Interventions
- filgrastim, gemcitabine hydrochloride, vinorelbine tartrate
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 93 more
- Conditions
- Cystic Fibrosis
- Interventions
- Lumacaftor, Ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 16 more
- Conditions
- Hemophilia A
- Interventions
- Nuwiq (low dose protocol), HEMLIBRA, Nuwiq (Atlanta protocol)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Sickle Cell Disease
- Interventions
- Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
- Biological
- Lead sponsor
- David Williams
- Other
- Eligibility
- 13 Years to 40 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Oakland, California • Sacramento, California + 4 more
- Conditions
- Intraocular Retinoblastoma
- Interventions
- liposomal vincristine sulfate, carboplatin, etoposide
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 6 Years
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2020
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Arcadia, California + 40 more